Bulk Pharmaceutical API Sources for BENZTROPINE MESYLATE

Bulk Pharmaceutical API Sources for BENZTROPINE MESYLATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		8584
ISpharm		I01-0267
MP Biomedicals		153626
MolPort		MolPort-003-844-725
AAA Chemistry		AR-1E7617

Bulk Active Pharmaceutical Ingredient (API) Sources for: BENZTROPINE MESYLATE

Last updated: July 28, 2025

---

Introduction

Benztropine Mesylate, a centrally acting anticholinergic, primarily treats Parkinson’s disease, drug-induced extrapyramidal symptoms, and other movement disorders. As a crucial component in pharmaceutical manufacturing, sourcing high-quality bulk APIs is fundamental for ensuring therapeutic efficacy, safety, and regulatory compliance. This article explores global sources for Benztropine Mesylate API, highlighting key manufacturers, sourcing considerations, and industry trends.

---

Overview of Benztropine Mesylate API

Benztropine Mesylate is chemically designated as 3α-Hyoscine methyl bromide (or bis-(tertiary-amino-ethyl-phenyl)-propane-1,2-diol mesylate). Its synthesis involves multiple complex steps, and sourcing involves understanding manufacturing capabilities, quality standards, and regulatory certifications. The API is available mainly from reputable chemical suppliers specializing in active pharmaceutical ingredients.

---

Global API Manufacturers and Suppliers

1. Major International API Producers

a) Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
As one of China's leading API producers, Hisun Pharmaceutical offers a comprehensive portfolio, including benztropine mesylate. The company emphasizes compliance with international standards such as cGMP, and its products are exported globally (1). Their manufacturing plants are certified by several regulatory authorities, including the FDA and EMA, ensuring quality assurance.

b) Jiangsu Hengrui Medicine Co., Ltd. (China)
Hengrui is a prominent Chinese pharmaceutical company with capabilities in synthetic chemical production. Although primarily focused on oncology and cardiovascular APIs, they manufacture complex alkaloid derivatives, including anticholinergic agents like benztropine mesylate (2).

c) Chemie Tecnologia SA (Brazil)
Specialized in active pharmaceutical ingredients and intermediates, Chemie Tecnologia supplies benztropine mesylate to South American markets. They adhere to international pharmacopeias and possess ISO and GMP certifications (3).

d) TCI Chemicals (Japan)
While TCI primarily supplies research-grade chemicals, they also supply pharmaceutical-grade APIs, including benztropine mesylate, with high purity standards suited for clinical and manufacturing use. Their strict quality protocols and high-purity products make them a reliable sourcing option (4).

e) Europharm International Ltd. (India)
Recognized for competitive pricing and consistent quality, Europharm produces benztropine mesylate conforming to USP, EP, and JP standards, serving both domestic and export markets (5).

2. Regional Suppliers and Distributors

Numerous regional distributors source APIs from international manufacturers, offering value-added services like packaging, labeling, and regulatory documentation. Notable distributors include:

• Alfa Chemistry (USA), offering GMP-grade benztropine mesylate for research and pharmaceutical use.
• Toronto Research Chemicals (Canada), providing high-purity benztropine mesylate suitable for analytical and research purposes.

---

Sourcing Considerations

a) Regulatory Compliance
Ensure suppliers hold relevant certifications such as cGMP, ISO, and regulatory approvals from agencies like the FDA or EMEA. Certification guarantees adherence to quality standards and batch-to-batch consistency.

b) Purity and Quality Standards
Manufacturers should provide detailed Certificates of Analysis, demonstrating potency (>98%), low residual solvents, and compliance with pharmacopeial requirements (USP, EP, JP).

c) Supply Chain Reliability
A stable supply chain minimizes risks associated with shortages or quality discrepancies. Long-term partnerships with established suppliers mitigates these risks.

d) Pricing and Lead Times
Pricing varies based on purity, quantity, and supplier location. Lead times depend on production capacity, regulatory clearance, and logistical factors.

e) Intellectual Property and Legal Considerations
Verify licensing agreements and patent statuses to avoid infringement issues, especially when sourcing from multiple jurisdictions.

---

Industry Trends and Developments

The API market is trending towards increased regulatory scrutiny, emphasizing transparency, traceability, and compliance. China and India remain dominant in low-cost bulk API production, but Western countries focus on high-quality, regulatory-approved sources with comprehensive supply chain validation. Due to global supply uncertainties (e.g., disruptions from the COVID-19 pandemic), diversified sourcing strategies are increasingly critical.

Additionally, advances in synthetic methodologies aim to optimize yield and reduce environmental impact, making suppliers with sustainable manufacturing practices more desirable.

---

Quality Assurance Protocols and Certifications

Suppliers should comply with the following standards:

• Current Good Manufacturing Practice (cGMP)
• ISO Certifications for quality management systems
• Pharmacopoeial compliance (USP, EP, JP)
• Batch-specific Certificates of Analysis
• Regulatory approvals for APIs exported to target markets

Engaging with suppliers who provide rigorous documentation ensures regulatory compatibility and minimizes downstream validation issues.

---

Cost Analysis and Procurement Strategies

Cost is influenced by API purity, quantity, and supplier location. Chinese suppliers typically offer lower prices, but import tariffs and regulatory acceptance must be considered. Specialty suppliers in Europe and North America often command premium prices due to higher manufacturing standards and stricter regulatory compliance.

Strategic procurement involves balancing cost with quality and regulatory needs through long-term agreements, vendor audits, and continuous quality surveillance.

---

Conclusion

The API market for benztropine mesylate features diverse global sources, with China, India, and South America as predominant manufacturing hubs. Ensuring regulatory compliance, high purity, supply chain stability, and quality documentation is indispensable for pharmaceutical companies sourcing this API. As the industry advances, integrating sustainability practices and enhancing traceability will further streamline sourcing strategies.

---

Key Takeaways

• Global sourcing options are extensive, with China and India leading the production of benztropine mesylate API.
• Regulatory compliance is paramount; verify suppliers' certifications, especially cGMP and pharmacopeial adherence.
• Quality assurance protocols—including Certificates of Analysis and batch validation—are critical for maintaining therapeutic safety.
• Supply chain diversification minimizes risks, especially amid ongoing global disruptions.
• Cost must be balanced with quality and regulatory requirements when selecting API suppliers.

---

FAQs

1. Is benztropine mesylate API widely available globally?
Yes. Multiple manufacturers across Asia, South America, and North America supply benztropine mesylate, offering a range of options from research-grade to pharmaceutical-grade APIs.

2. What regulatory certifications should I seek from API suppliers?
Prefer suppliers with cGMP, ISO certifications, and certificates that demonstrate compliance with pharmacopeia standards such as USP, EP, or JP.

3. How can I verify the quality of benztropine mesylate API?
Request detailed Certificates of Analysis, review purity levels (>98%), residual solvent analysis, and perform validation testing upon receipt if necessary.

4. Are there concerns about intellectual property when sourcing from certain regions?
Yes. Ensure licensing agreements are in place, and verify that sourcing complies with patent laws to avoid infringement.

5. How does global supply chain disruption impact sourcing?
It can lead to delays and shortages. Diversifying suppliers and maintaining buffer stock can mitigate these risks.

---

References

1. Zhejiang Hisun Pharmaceutical Co., Ltd. Official website.
2. Jiangsu Hengrui Medicine Co., Ltd. Corporate disclosures.
3. Chemie Tecnologia SA Product catalog.
4. TCI Chemicals. Product datasheets.
5. Europharm International Ltd. Certification documentation.